Articles Archives

What it Takes to Launch a Modern Supply Chain Operation

As we move closer to launch on August 17, 2026, the Santa Ana facility is transitioning from a construction project to an operational asset representing a milestone that required months of coordinated work across engineering, facilities, operations, product, quality, IT, and supply chain teams. A facility may represent the physical footprint, but true operational readiness is measured by systems, processes, people, equipment, compliance, and execution.

Read More

Expert Q&A: Going Deeper on Early Supply Chain Strategy for CGT Programs

Advanced therapy developers rarely have the luxury of perfect timing. Programs are often moving toward the next milestone with limited resources, data that’s evolving in real time, and pressure to make decisions before every variable is fully understood. That reality was at the center of the recent webinar, “Prevent Advanced Therapy Program Delays with Early Supply Chain Strategy,” where panelists discussed how early decisions around logistics, cryopreservation, packaging, site readiness, documentation, and cross-functional alignment can influence everything downstream.

Read More

Cryoport Systems Wins Best Cell & Gene Therapy Supplier Award for Cold Chain Logistics at APCGTEA 2026

Cryoport Systems is pleased to announce that we have been named Best Cell & Gene Therapy Supplier – Cold Chain Logistics at the 2026 Asia-Pacific Cell & Gene Therapy Excellence Awards (APCGTEA). This recognition carries special meaning as it reflects the voice of the global advanced therapies community.

Read More

Building the Foundation: Our New Global Supply Chain Center in Santa Ana, California

End-to-end supply chain execution is a competitive advantage. Speed, reliability, and adaptability define how businesses deliver for customers. That’s why we’ve invested in a consolidated 86,500‑square‑foot Global Supply Chain Center (GSCC) in Santa Ana, California, a strategic step forward in strengthening the backbone of our global operations.

Read More

Cryoport Systems’ IntegriCell® Services Selected by Verismo Therapeutics to Support Clinical KIR-CAR T Cell Therapy Programs

Cryoport Systems is pleased to share that Verismo Therapeutics has selected IntegriCell® cryopreservation services to support two clinical KIR-CAR T cell therapy programs: SynKIR™-110, currently being evaluated in the STAR-101 Phase 1 trial for patients with advanced mesothelin-expressing solid tumors, and SynKIR™-310, currently being evaluated in the CELESTIAL-301 Phase 1 trial for patients with relapsed or refractory B-cell non-Hodgkin lymphomas. Both candidates are in human clinical trials, with initial Phase 1 data presented at the AACR 2026 Annual Meeting.

Read More

Now Available On Demand: Preventing Advanced Therapy Program Delays with Early Supply Chain Strategy

Advanced therapy programs move through development under intense pressure. Teams are working to reach the clinic, generate data, satisfy regulatory expectations, scale operations, and ultimately deliver therapies to patients who may have limited or no other options. In that environment of competing priorities, all of which are important at the same time, supply chain decisions can become easy to defer. But as a recent roundtable webinar with XTalks made clear, decisions around cryopreservation, logistics, packaging qualification, site readiness, and documentation are not just operational details that can be solved later.

Read More

New eBook: Flexible Infrastructure for Smarter Scale in Advanced Therapies

Advanced therapy developers are being asked to do more with less. Programs need to move faster, reach more patients, support more geographies, and stay ready for evolving regulatory expectations, all while capital remains tightly managed. Cryoport Systems’ new eBook, Flexible Infrastructure: Minimizing CapEx for Smarter Scale in Advanced Therapies, explores that question across the advanced therapy lifecycle. The eBook looks at how developers can preserve capital, reduce operational risk, and avoid overbuilding fixed infrastructure before their programs are ready to use it. 

Read More

Mark Sawicki Joins Base to Base Biotech to Discuss the Future of Cell and Gene Therapy Logistics

Mark Sawicki, President and CEO of Cryoport Systems, recently joined host Jim Cornall on the Base to Base Biotech podcast for a wide-ranging conversation on the evolving cell and gene therapy landscape and the role of specialized supply chain infrastructure in supporting patient access.

Read More

New ISCT Thought Leadership Explores Why Growth in CGT Demands a Different Operating Model

The way the industry thinks about scale is starting to shift. For decades, growth in biopharmaceutical development has followed a familiar pattern. As programs advance, manufacturing expands and throughput increases, allowing therapies to move from limited, early-phase clinical trial settings into broader patient populations. A new article from Cryoport Systems published through the International Society for Cell & Gene Therapy (ISCT) explores how scale behaves differently in advanced therapies and why the industry may need to rethink the operating models used to support it.

Read More